Benchmark catalog

Clinical Trial Forecasting Benchmarks

Each benchmark is a real, pivotal trial readout. Models forecast the outcome before it becomes public, then we score them against the ground truth. Pick any disease, drug, or company below to dive in.

Benchmarks
17
Resolved
7
Diseases
15
Companies
16

Browse by

Diseases
15 pages
Drugs
17 pages
Companies
16 pages
Targets & genes
13 pages

Cardiometabolic

2 trials
OpenPhase 3

ATTAIN-MAINTAIN (orforglipron) weight maintenance after switching from Wegovy or Zepbound

Orforglipron · Obesity

Dec 18, 2025Clinical Trials
OpenPhase 2b

ACCESS (aleniglipron) Phase 2b obesity

Aleniglipron · Obesity

Dec 8, 2025Clinical Trials

Dermatology

2 trials
OpenPhase 2b

DUPLEX-AD (JNJ-95475939 / JNJ-5939) atopic dermatitis

JNJ-95475939 · Atopic dermatitis

Dec 26, 2025Clinical Trials
OpenPhase 2b

REZOLVE-AA (rezpegaldesleukin) Phase 2b alopecia areata

Rezpegaldesleukin · Alopecia areata

Dec 16, 2025Clinical Trials

Neuromuscular

2 trials
ResolvedPhase 3

HOPE-3 Phase 3: deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)

Deramiocel · Duchenne muscular dystrophy

Clinical Trials
ResolvedPhase 1/2

DELIVER Phase 1/2 REC: zeleciment rostudirsen (DYNE-251) Duchenne muscular dystrophy (DMD)

Zeleciment rostudirsen · Duchenne muscular dystrophy

Clinical Trials

Oncology

2 trials
OpenPhase 3

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

Ceralasertib · Non-small cell lung cancer

Dec 22, 2025Clinical Trials
ResolvedPhase 3

RINGSIDE Phase 3: varegacestat in desmoid tumors

Varegacestat · Desmoid tumors

Clinical Trials

Ophthalmology

2 trials
OpenPhase 3

UplighTED (efgartigimod) Phase 3 in thyroid eye disease

Efgartigimod · Thyroid eye disease

Dec 15, 2025Clinical Trials
ResolvedPhase 3

DRAGON Phase 3: tinlarebant (5 mg daily) in adolescent Stargardt disease type 1 (STGD1)

Tinlarebant · Stargardt disease

Dec 1, 2025Clinical Trials

Respiratory & ENT

2 trials
OpenPhase 2b

BiRCh (brensocatib) Phase 2b for CRSsNP

Brensocatib · Chronic rhinosinusitis without nasal polyps

Dec 17, 2025Clinical Trials
OpenPhase 3

InnovAATe (inhaled AAT) Phase 3 AATD lung disease

Inhaled alpha-1 antitrypsin · Alpha-1 antitrypsin deficiency

Dec 8, 2025Clinical Trials

Rheumatology

2 trials
OpenPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials
ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials

Allergy & Immunology

1 trial
ResolvedPhase 3

VITESSE Phase 3: VIASKIN® Peanut patch 250 µg in peanut-allergic children aged 4–7 years

VIASKIN Peanut patch · Peanut allergy

Dec 16, 2025Clinical Trials

Endocrinology

1 trial
ResolvedPhase 3

Casppian Phase 3: FP-001 leuprolide mesylate 42 mg q6mo Central Precocious Puberty (CPP)

FP-001 (leuprolide mesylate) · Central precocious puberty

Dec 24, 2025Clinical Trials

Nephrology

1 trial
OpenPhase 3

GOOD-IDES-02 (imlifidase) Phase 3 anti-GBM

Imlifidase · Anti-GBM disease

Dec 16, 2025Clinical Trials